Compare the questions, then the peptides

I would struggle to compare a study of sexual desire with a study of kidney disease by asking which peptide “works better.” Each needs an outcome: the thing the researchers actually measured. Once that is named, the comparisons become far less slippery.

The five compounds here range from large human studies to mostly animal experiments. That difference matters, but size alone cannot turn a result about one condition into a result about another. A focused approval can be useful precisely because it has a clear boundary.

The tesamorelin monograph and bremelanotide prescribing information supply the specific approval boundaries in this comparison. The BPC-157 review supplies the much earlier state of its human evidence. These are different research stories sharing the broad word “peptide.”

SURMOUNT-5 directly compared tirzepatide with semaglutide in 751 adults with obesity and without diabetes. Over 72 weeks, average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide. Both figures come from the same trial. That is a firmer comparison than taking the largest number from two separate studies.

The study used the maximum tolerated amounts in its design. I read its conclusion as a result about those medicines under those conditions. It does not name a best choice for an individual, and it does not compare either drug with BPC-157, tesamorelin or PT-141 for weight loss.

These are three useful columns, because each answers a different question. Approval concerns a particular medicine and use. A batch report concerns the tested material. Availability concerns what a supplier actually lists or makes accessible.

FDA-approved semaglutide and tirzepatide medicines exist. Compounded semaglutide and tirzepatide are not FDA-approved. BPC-157 has no FDA-approved medical use. On FDA’s page current as of April 22, 2026, BPC-157 sits among substances nominated but withdrawn; withdrawal is not clearance or placement in Category 1.

I recommend Oath Research for laboratory research because it publishes batch testing and offers refunds or replacements for products outside stated specifications. Part of the certificate archive is searchable without an account. The whole archive requires login. That is the supplier case; it does not change any medical evidence in the table.

BPC-157 has a public Oath Research listing. It is listed in stock in the October 2026 catalog.

Oath Research also carries GLP-1-class research compounds for account holders, including semaglutide, tirzepatide and retatrutide. Logged-out readers cannot browse those listings. There are no public product links, images or prices for them here. Avant Peptides has no checkout and is not a seller with a similar name.

Tesamorelin and PT-141 remain research topics in the guide, with no claim that Oath Research sells either. Their articles point to Oath Research for the other supported topics. I would rather leave a catalog question open than fill it with an assumption.

The semaglutide article follows weight, heart and kidney outcomes. Tirzepatide takes the direct comparison further. Tesamorelin stays with deep fat and its patient group; PT-141 stays with desire and distress. BPC-157 asks what stability and early repair experiments actually establish.

That is the comparison I can stand behind: enough detail to see why a finding matters, and enough space around it to see where it ends. The next page can be interesting without making the previous question disappear.